Leap therapeutics announces first patient enrolled in part c of phase 2 distinguish study of dkn-01 in combination with tislelizumab for the treatment of gastric or gastroesophageal junction cancer

Cambridge, mass. , oct. 12, 2022 /prnewswire/ -- leap therapeutics, inc. (nasdaq:lptx), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the first patient has been enrolled in the randomized controlled part c of the ongoing distinguish study to evaluate dkn-01, leap's anti-dickkopf-1 (dkk1) antibody, in combination with tislelizumab, beigene's anti-pd-1 antibody, and chemotherapy compared to a tislelizumab and chemotherapy control arm, in patients with gastric or gastroesophageal junction cancer (g/gej).
LPTX Ratings Summary
LPTX Quant Ranking